Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among.

Slides:



Advertisements
Similar presentations
Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.
Advertisements

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Cutaneous Lupus Erythematosus Disease Area and.
CARRA Lupus Work Group 2016 Annual Scientific Meeting APRIL 17, 2016 TORONTO, CANADA 1.
F.M. Lewis, F.M. Tatnall, S.S. Velangi, C. B. Bunker,
Awareness and Knowledge of Clinical Practice Guidelines for Systemic Lupus Erythematosus among Family Medicine Faculty and Residents Stephen James Kelton,
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Narrowband-UVB treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments K. Boswell,1 H. Cameron,1 J.
Dermatomyositis: A diagnostic dilemma
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial  Lauren Okon, MD, Misha Rosenbach, MD, Michael.
Misha Rosenbach, Dedee F
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus  Joerg Albrecht, Lynne.
Meera Tarazi, BA, Kumpol Aiempanakit, MD, Victoria P. Werth, MD 
Jack C. O’Brien, Benjamin F. Chong 
Journal of Investigative Dermatology
Laura J. Dixon1,2, Sara M. Witcraft1, Nancye K. McCowan2, & Robert T
Jack C. O’Brien, Benjamin F. Chong 
Validity of the EQ-5D in pemphigus vulgaris and foliaceus patients
To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in Hidradenitis Suppurativa Alicia Pavon Blanco,1.
Anatomical Site Differences of Sodium Laurylsulphate Induced Irritation: Randomised controlled trial D Leskur1, J Bukić1, A Petrić1,2, L Zekan1,2, D Rušić1,
Association of CCL2 with systemic inflammation in Schnitzler’s syndrome Karoline Krause, Robert Sabat, Ellen Witte-Händel, Anne Schulze, Viktoria Puhl,
Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase II clinical study evaluating the non-inferiority.
Polyomaviruses of the Skin: Integrating Molecular and Clinical Advances in an Emerging Class of Viruses Jessica C. Sheu1*, Jessica Tran1*, Peter L. Rady2,
A.D. Irvine1,2,3 and P. Mina-Osorio4
Sub-Populations of Dermal Skin Fibroblasts Secrete Distinct Extracellular Matrix: Implications for Using Skin Substitutes in the Clinic Ghetti, M., Topouzi,
Comparison of patient (POEM), observer (EASI, SASSAD, TIS) and corneometry measures of emollient effectiveness in children with eczema: findings from the.
Systematic review of atopic dermatitis disease definition in studies using routinely-collected health data M.P. Dizon, A.M. Yu, R.K. Singh, J. Wan, M-M.
M. T. Svendsen1,2. ,, M. T. Ernst3. , K. E. Andersen1,2,4, F
Cancer is not a risk factor for bullous pemphigoid
Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway Ingrid Snekvik1,2, Tom I L Nilsen1, 3, Pål R Romundstad1,
Lack of Confidence Interval Reporting in Dermatology: A Call to Action
Fumaric acid esters in combination with a 6-week course of narrow-band UVB provides for an accelerated response as compared to fumaric acid esters monotherapy.
Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa J.R. Ingram*,
Kristen Foering, MD, Aileen Y. Chang, MD, Evan W
Impact of Acute Stress on Itch Sensation and Scratching Behavior in Atopic Dermatitis Patients and Healthy Controls H. Mochizuki1, 2, M. J. Lavery2, L.
High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of individuals Ulrik C. Winsløw, Børge.
Gottlieb AB14, Christensen R2,15, Jemec GBE1
Validation and Reliability of a Disease-Specific Quality of Life Measure in Patients with Cutaneous Lupus Erythematosus: CLEQoL M.E. Ogunsanya,1 S.K. Cho,2.
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.
Cumulative exposure to biologics and risk of cancer in psoriasis patients: a meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom.
C.I.M. Busard, J.Y.C. Nolte, M.C. Pasch, Ph.I. Spuls
Primary paediatric cutaneous mucinoses
Applying the phenotype approach for rosacea to practice and research
Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis Kyriakou, A. Patsatsi,
Impact of skin damage on health-related quality of life.
K. A. Su,1,2 L. A. Habel,3 N. S. Achacoso,3 G. D. Friedman,3 M. M
Methotrexate and azathioprine in severe atopic dermatitis: A 5-year follow up study of a randomised controlled trial L.A.A. Gerbens, S.A.S Hamann, M.W.D.
Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: A cross-sectional analysis of the National Inpatient Sample.
T. Tzellos1,2; H. Yang3; F. Mu3; B. Calimlim4; J. Signorovitch3
First Evaluation of the Behavioral Addiction Indoor Tanning Screener (BAITS) in a nationwide representative sample K. Diehl, T. Görig, E.W. Breitbart,
Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE S. Lundin,1,2 C.F. Wahlgren,3,4.
F.M. Lewis, F.M. Tatnall, S.S. Velangi, C. B. Bunker,
A. Al-Janabi1, Z. K. Jabbar-Lopez2, C.E.M. Griffiths1, Z.Z.N. Yiu1
C. M. Olsen, L. F. Wilson, A. C. Green, N. Biswas, J. Loyalka, D. C
Surgical re-excision versus observation for histologically dysplastic nevi: a systematic review of associated clinical outcomes K.T. Vuong1, J. Walker2,
An App Supporting Psoriasis Patients Improves Adherence to Topical Treatment: A randomised controlled trial M.T. Svendsen,1,2,3 F. Andersen,1,4 K.H. Andersen,4.
Use of the hCONSORT Criteria as a Reporting Standard for Herbal Interventions for Common Dermatoses – A Systematic Review J. Ornelas, MD, MAS 1, E. Routt,
Atopic dermatitis, educational attainment and psychological functioning: a national cohort study Authors: Jevgenija Smirnova1,2, Laura von Kobyletzki1,3,
Prevalence and determinants of seborrhoeic dermatitis in a middle aged and elderly population: the Rotterdam Study M.G.H. Sanders, MD1, L.M. Pardo, MD,
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
M. Ormond, H. McParland, A. N. A. Donaldson, M. Andiappan, R. J
Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: Report of the Dutch Cutaneous Lymphoma Group Melchers RC1, Willemze.
Patient reported outcome measures for facial skin cancer: a systematic review and evaluation of the quality of their measurement properties Tom Dobbs,
Proposal of a new scoring formula for the DLQI in psoriasis
RCT pilot study comparing localised immersion PUVA with localised narrowband ultraviolet B (NBUVB) for treatment of palmar hand eczema D. Brass1, T.
Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary.
Authors: S. Brill1, E. Sprecher2, F. J. D. Smith3, N. Geva4, H
Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs P. Soares, 1 K. Fidler, 1 J. Felton,
The prevalence of psychological co-morbidity in people with vitiligo: a systematic review and meta-analysis O. Osinubi, M.J. Grainge, L. Hong, A. Ahmed,
Tschandl P1,2, Argenziano G3, Razmara M4, Yap J4
Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study  Jeanette.
Presentation transcript:

Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists Carolyn J. Kushner & Meera Tarazi, R.G. Gaffney, R. Feng, K. Ardalan, H. Brandling-Bennett, L. Castelo-Soccio, J.C. Chang, Y.E. Chiu, S. Gmuca, R.D. Hunt, P.J. Kahn, A.M. Knight, J. Mehta, D.R. Pearson, J.R. Treat, J. Wan, A.C. Yeguez, J.S.S. Concha, B. Patel, J. Okawa, L.M. Arkin & V.P. Werth University of Pennsylvania British Journal of Dermatology. DOI: 10.111/bjd.17012

Lead Investigators: Co-first authors: Carolyn J. Kushner (Left), and Meera Tarazi (Right) Principal Investigator: Victoria P. Werth, M.D. (Middle)

Introduction What’s already known? Cutaneous lupus erythematosus (CLE) refers to skin manifestations of the autoimmune disease lupus erythematosus (LE) Skin involvement is one of the most common presenting signs of systemic lupus erythematosus (SLE) Skin evaluation is critical to making a diagnosis and monitoring disease progression Patients may also present with isolated CLE without systemic disease, which can be disfiguring and distressing to patients

What’s already known? Lupus has been extensively researched in the adult population Far fewer studies exist in the paediatric population Need to validate disease severity tools for children with lupus to advance understanding about the disease and treatment The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) has been established as a reliable outcome measure for CLE in adults and is used in clinical trials

Objective This study was aimed to validate the reliability of the CLASI in the paediatric CLE population Paediatric CLE can manifest differently from CLE in adults This validation will allow clinical trials to reliably assess treatment efficacy in CLE

The CLASI The CLASI scores activity and damage separately 1) Disease activity 2) Damage from prior activity Accounts for: Skin Mucous Membranes Alopecia

Methods Patients and Physician Attendees: 11 pediatric patients with active CLE 5 pediatric rheumatologists and 1 pediatric rheumatology fellow 4 pediatric dermatologists and 2 dermatology fellows

Methods Study day: Physicians completed a 45-min training session on how to assess CLE using 2 outcome measures: CLASI Physician Global Assessment (PGA) Physicians individually rated all 11 patients using both tools Each physician reassessed 2 patients (for intra-rater reliability) Physicians completed an exit survey Patients completed a childhood quality of life survey

Results: Inter-Rater Reliability CLASI activity scores: excellent (ICC>0.90) inter-rater reliability among both dermatologists and rheumatologists. The PGA activity scores: good (ICC between 0.77-0.73) inter-rater reliability for both specialties. *ICC – intraclass correlation coefficient ICC 95% CI Dermatologists CLASI Activity 0.95 0.90-0.99 CLASI Damage 0.76 0.56-0.91 PGA Activity 0.77 0.57-0.92 PGA Damage 0.50 0.25-0.78 Rheumatologists 0.91 0.81-0.97 0.43 0.19-0.74 0.73 0.52-0.90 0.65 0.42-0.86

Results Inter-rater reliability for CLASI and PGA activity scores were about the same: Dermatologists (CLASI ICC=0.95, PGA ICC=0.77) Rheumatologists (CLASI ICC=0.91, PGA ICC=0.73) Inter-rater damage scores: For CLASI, higher in the dermatologist group (ICC=0.76) compared to the rheumatologists (ICC=0.43). For PGA, higher in the rheumatologists (ICC=0.65) compared to the dermatologists (ICC=0.50). Exit survey showed that the majority of physicians found the CLASI to be easier to use than the PGA.

Results: Intra-Rater Reliability ICC 95% CI CLASI activity scores: excellent (ICC>0.90) intra-rater reliability among both dermatologists and rheumatologists. The PGA activity scores: good (ICC between 0.77-0.73) intra-rater reliability for rheumatologists, and excellent (ICC>0.90) for dermatologists. Dermatologists CLASI Activity 0.995 0.98-0.999 CLASI Damage 0.87 0.63-0.96 PGA Activity 0.89 0.69-0.97 PGA Damage 0.76 0.37-0.92 Rheumatologists 0.96 0.88-0.99 0.38-0.92 0.73 0.31-0.91

Conclusions CLASI activity score showed excellent (ICC>0.81) inter- rater reliability compared to the PGA Little variation between dermatologists and rheumatologists Majority of physicians found the CLASI to be an easier tool to use Can be used in future clinical trials for pediatric CLE Will allow clinical trials to reliably assess treatment efficacy in CLE Albrecht Werth 2005

Pediatric CLASI Research Team They specifically asked for a photo of the research team. Back row (left to right): Heather A. Brandling-Bennett, James R. Treat, Joy Wan, Philip J. Kahn, Jay Mehta, David R. Pearson, and Andrea M. Knight. Second Row (left to right): Leslie Castelo-Soccio, Sabrina Gmuca, Joyce C. Chang, Victoria P. Werth, Lisa M. Arkin, Julie Burroughs, Joyce Okawa, and Kaveh Ardalan. Front Row (left to right): Meera Tarazi, Carolyn J. Kushner, Rebecca G. Gaffney, Josef S. S. Concha, and Basil Patel.

Call for correspondence Why not join the debate on this article through our correspondence section? Rapid responses should not exceed 350 words, four references and one figure Further details can be found here